# Targeted therapy # LUSPATERCEPT # First time in this region # Hematologist The benefit of giving Targeted Therapy to the patient who is transfusion dependent....When this drug just launched in India in 2023..and first time in this region ..you have the opportunity to treat the patient with targeted therapy "LUSPATERCEPT"..... luspatercept (Reblozyl) was approved by the US Food and Drug Administration for the treatment of anemia in adults with IPSS-R Very low-to Intermediate-risk MDS with ring sideroblasts (RS), and if patients were SF3B1-mutation positive...who have failed ESA therapy and require ≥ 2 RBC units/8 weeks (FDA)